Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642182 · ClinicalTrials.gov registry record · Phase 1
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
A Phase 1 study of Psoriasis, sponsored by SFA Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 3
- Study locations
NCT05642182 is a Phase 1 study of Psoriasis that is actively recruiting participants, run by SFA Therapeutics. The registered enrollment target is 90 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT05642182, a Phase 1 study of Psoriasis, is actively recruiting participants, sponsored by SFA Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms.
Conditions Studied
Interventions
- DRUG SFA002
Study Locations (3)
Florida
- NuLine Clinical Trial Center - Pompano Beach
North Dakota
- Axis Clincals USA/ Red River Research Patners. LLC - Fargo
Pennsylvania
- Temple University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-03-31 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05642182
The ClinicalTrials.gov registry entry for NCT05642182 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (82% lower). The listed sponsor is SFA Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which SFA002 is the first listed.
NCT05642182 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, North Dakota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05642182 about?
NCT05642182 is a clinical study titled "Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques". The purpose of this study is to determine the safety, metabolism and potential effect of drug product SFA-002 on mild moderate and severe chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed...
What is the current status of trial NCT05642182?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-03-31. Estimated completion is 2025-07-31.
What conditions does trial NCT05642182 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT05642182?
The interventions under investigation include: SFA002 (DRUG).
Who is sponsoring clinical trial NCT05642182?
This trial is sponsored by SFA Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05642182 being conducted?
This trial has 3 study locations across Florida, North Dakota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
-
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.